Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, outlines an assessment of baseline characteristics and safety outcomes in HIMALAYA trial participants who were rechallenged with tremelimumab after being treated with the STRIDE regimen (single dose of tremelimumab plus regular-interval durvalumab) (Abstract 541).
Samuel J. Klempner, MD, of Massachusetts General Hospital, discusses results from the phase II ILUSTRO trial, which evaluated the combination of the anti-CLDN18.2 antibody zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive; HER2-negative; locally advanced, unresectable, or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma (Abstract LBA284).
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, reviews the goals of the upcoming phase III ARTEMIDE-HCC01 trial, which will examine the efficacy and safety of rilvegostomig (a novel bispecific anti–PD-1/anti-TIGIT antibody) plus bevacizumab with or without tremelimumab as first-line treatment for unresectable hepatocellular carcinoma (Abstract TPS612).
Elizabeth Smyth, MD, of the Oxford NIHR Biomedical Research Centre, Churchill Hospital, presents findings from an analysis of the MATTERHORN trial, a phase III study that examined fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus durvalumab in patients with resectable gastric/gastroesophageal junction cancer. Dr. Smyth discusses rates of FLOT discontinuation along with event-free survival based on FLOT completion status in the trial (Abstract 343).
